CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine

Infection and Immunity

Volumn 73, Issue 2, 2005, Pages 828-833

  Xie, Hang ^a   Gursel, Ihsan ^a   Ivins, Bruce E ^b   Singh, Manmohan ^c   O'Hagan, Derek T ^c   Ulmer, Jeffrey B ^c   Klinman, Dennis M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Dept of Immunol and Molec Biology Bldg 1425 U States Army Med R   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; IMMUNOGLOBULIN G; OLIGODEOXYNUCLEOTIDE; POLYGLACTIN;

ADSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; CELL KILLING; CELL PROTECTION; CONTROLLED STUDY; CPG ISLAND; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; MALE; MICE; MICROSPHERES; OLIGODEOXYRIBONUCLEOTIDES; POLYGLACTIN 910; TIME FACTORS;

EID: 12844272901     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.2.828-833.2005     Document Type: Article

References (42)

1. Agresti, A., and B. A. Coull. 1996. Order-restricted tests for stratified comparisons of binomial proportions. Biometrics 52:1103-1111.
2. Ballas, Z. D., W. L. Rasmussen, and A. M. Krieg. 1996. Induction of NK activity in murine and human cells by CpO motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157:1840-1847.
3. Briones, M., M. Singh, M. Ugozzoli, J. Kazzaz, S. Klakamp, G. Ott, and D. O'Hagan. 2001. The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery. Pharm. Res 18:709-712.
4. Davis, H. L., I. Suparto, R. Weeratna, Jumintarto, D. Iskandriati, S. Chamzah, A. Ma'ruf, C. Nente, A. M. Krieg, Heriyanto, W. Smits, and D. Sajuthi. 2000. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 18:1920-1924.
5. Davis, H. L., R. Weeranta, T. J. Waldschmidt, L. Tygrett, J. Schorr, and A. M. Krieg. 1998. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160:870-876.
6. Denis-Mize, K. S., M. Dupuis, M. L. MacKichan, M. Singh, B. Doe, D. O'Hagan, J. B. Ulmer, J. J. Donnelly, D. M. McDonald, and G. Ott. 2000. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther. 7:2105-2112.
7. Denis-Mize, K. S., M. Dupuis, M. Singh, C. Woo, M. Ugozzoli, D. T. O'Hagan, J. J. Donnelly III, G. Ott, and D. M. McDonald. 2003. Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell. Immunol. 225:12-20.
8. Friedlander, A. M., and P. S. Brachman. 1998. Anthrax, p. 729-739. In S. A. Plotkin and E. A. Mortimer (ed.), Vaccines. W. B. Saunders, Philadelphia, Pa.
9. Geier, D. A., and M. R. Geier. 2002. Anthrax vaccination and joint related adverse reactions in light of biological warfare scenarios. Clin. Exp. Rheumatol. 20:217-220.
10. Gursel, I., M. Gursel, K. J. Ishii, and D. M. Klinman. 2001. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J. Immunol. 167:3324-3328.
11. Halperin, S. A., G. Van Nest, B. Smith, S. Abtahi, H. Whiley, and J. J. Eiden. 2003. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 21:2461-2467.
12. Halpern, M. D., R. J. Kurlander, and D. S. Pisetsky. 1996. Bacterial DNA induces murine interferon-gamma production by stimulation of 1L-12 and tumor necrosis factor-alpha. Cell. Immunol. 167:72-78.
13. Hanna, P. 1998. Anthrax pathogenesis and host response. Curr. Top. Microbiol. Immunol. 225:13-35.
14. Helkenwalder, M., M. Polymenidou, T. Junt, C. Sigurdson, H. Wagner, S. Akira, R. Zinkernagel, and A. Aguzzi. 2004. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 10:187-192.
15. Ivins, B. E., M. L. Pitt, P. F. Fellows, J. W. Farchaus, G. E. Benner, D. M. Waag, S. F. Little, G. W. Anderson, Jr., P. H. Gibbs, and A. M. Friedlander. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16:1141-1148.
16. Ivins, B. E., and S. L. Welkos. 1988. Recent advances in the development of an improved, human anthrax vaccine. Eur. J. Epidemiol. 4:12-19.
17. Ivins, B. E., S. L. Welkos, G. B. Knudson, and S. F. Little. 1990. Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect. Immun. 58:303-308.
18. Ivins, B. E., S. L. Welkos, S. F. Little, M. H. Crumrine, and G. O. Nelson. 1992. Immunization against anthrax with Bacillus anihracis protective antigen combined with adjuvants. Infect Immun. 60:662-668.
19. Jones, T. R., N. Obaldia, R. A. Gramzinski, Y. Charoenvit, N. Kolodny, S. Kitov, H. L. Davis, A. M. Krieg, and S. L. Hoffman. 1999. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenic vaccine in Aotus monkeys. Vaccine 17:3065-3071.
20. Klinman, D. M. 2004. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4:249-258.
21. Klinman, D. M., H. Xie, S. Little, D. Currie, and B. Ivins. 2004. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine 22:2881-2886.
22. Klinman, D. M., K. M. Barnhart, and J. Conover. 1999. CpG motifs as immune adjuvants. Vaccine 17:19-25.
23. Klinman, D. M., A. Yi, S. L. Beaucage, J. Conover, and A. M. Krieg. 1996. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, 1L-12 and IFNg. Proc. Natl. Acad. Sci. USA 93:2879-2883.
24. Krieg, A. M., A. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-548.
25. Lane, H. C., J. L. Montagne, and A. S. Fauci. 2001. Bioterrorism: a clear and present danger. Nat. Med. 7:1271-1273.
26. Little, S. F., and B. E. Ivins. 1999. Molecular pathogenesis of Bacillus anthracis infection. Microbes Infect. 1:131-139.
27. Little, S. F., B. E. Ivins, P. F. Fellows, M. L. Pitt, S. L. Norris, and G. P. Andrews. 2004. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22:422-430.
28. O'Hagan, D., M. Singh, M. Ugozzoli, C. Wild, S. Barnett, M. Chen, M. Schaefer, B. Doe, G. R. Otten, and J. B. Ulmer. 2001. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J. Virol. 75:9037-9043.
29. Oishi, K., N. L. Koles, G. Guelde, and M. Pollack. 1992. Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity. J. Infect. Dis. 165:34-45.
30. Pittman, P. R., P. H. Gibbs, T. L. Cannon, and A. M. Friedlander. 2001. Anthrax vaccine: short-term safety experience in humans. Vaccine 20:972-978.
31. Pittman, P. R., G. Kim-Ahn, D. Y. Pifat, K. Coonan, P. Gibbs, S. Little, J. G. Pace-Templeton, R. Myers, G. W. Parker, and A. M. Friedlander. 2002. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 20:1412-1420.
32. Quinn, C. P., and P. C. Turnbull. 1998 Anthrax, p. 799-818. In M. Ballow and M. Sussman (ed.), Topley and Wilson's microbiology and microbial infections Collier, London, England.
33. Ready, T. 2004. US soldiers refuse to fall in line with anthrax vaccination scheme. Nat. Med. 10:112.
34. Sanceau, J., T. Kaisho, T. Hirano, and J. Wietzerbin. 1995. Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF-kB, and Sp1 transcription factors. J. Biol. Chem. 270:27920-27931.
35. Singh, M., J. Kazzaz, M. Ugozzoli, J. Chesko, and D. T. O'Hagan. 2004. Charged polylactide co-glycolide microparticles as antigen delivery systems. Expert Opin. Biol Ther 4:483-491.
36. Singh, M., X. M. Li, J. P. McGee, T. Zamb, W. Koff, C. Y. Wang, and D. T. O'Hagan. 1997. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. Vaccine 15:475-481.
37. Singh, M., G. Ott, J. Kazzaz, M. Ugozzoli, M. Briones, J. Donnelly, and D. T. O'Hagan. 2001. Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharm. Res 18:1476-1479.
38. Vajdy, M., and D. T. O'Hagan. 2001. Microparticles for intranasal immunization. Adv. Drug Deliv. Rev 51:127-141.
39. Valiante, N. M., D. T. O'Hagan, and J. B. Ulmer. 2003. Innate immunity and biodefence vaccines. Cell. Microbiol 5:755-760.
40. Verthelyi, D., R. T. Kenney, R. A. Seder, A. A. Gam, B. Friedag, and D. M. Klinman. 2002. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J. Immunol. 168:1659-1663.
41. Welkos, S., S. Little, A. Friedlander, D. Fritz, and P. Fellows. 2001. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147:1677-1685.
42. Welkos, S. L., and A. M. Friedlander. 1988. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb. Pathog. 5:127-139.